AIMC Topic: Tamoxifen

Clear Filters Showing 1 to 7 of 7 articles

Machine learning Nomogram for Predicting endometrial lesions after tamoxifen therapy in breast Cancer patients.

Scientific reports Jan 6, 2025
Objective Endometrial lesions are a frequent complication following breast cancer, and current diagnostic tools have limitations. This study aims to develop a machine learning-based nomogram model for predicting the early detection of endometrial les...
Risk Factors Adult Breast Neoplasms Machine Learning Retrospective Studies Female Antineoplastic Agents, Hormonal Tamoxifen Middle Aged Premenopause Nomograms Humans Endometrium
View on PubMed DOI

Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.

European journal of cancer (Oxford, England : 1990) Dec 21, 2017
BACKGROUND: Prior randomised controlled trials on adjuvant hormonal therapy included HER2 patients; however, a differential effect of aromatase inhibitors (AIs) versus tamoxifen (TAM) may have been missed in ER+/HER2+ patients that comprise 7-15% of ...
Tamoxifen Antineoplastic Agents, Hormonal Chemotherapy, Adjuvant Humans Female Aged Aromatase Inhibitors Cohort Studies Age of Onset Kaplan-Meier Estimate Adult Disease-Free Survival Receptor, ErbB-2 Receptors, Estrogen Breast Neoplasms Netherlands Middle Aged Proportional Hazards Models
View on PubMed DOI

Integration of a prognostic gene module with a drug sensitivity module to identify drugs that could be repurposed for breast cancer therapy.

Computers in biology and medicine Jan 7, 2015
BACKGROUND: Efficiently discovering low risk drugs is important for drug development. However, the heterogeneity in patient population complicates the prediction of the therapeutic efficiency. Drug repositioning aiming to discover new indications of ...
Humans Prognosis Databases, Genetic Tamoxifen Gene Ontology Female Breast Neoplasms Pharmacogenetics Androstadienes
View on PubMed DOI

Evaluation of machine learning algorithms and computational structural validation of CYP2D6 in predicting the therapeutic response to tamoxifen in breast cancer.

European review for medical and pharmacological sciences Dec 1, 2024
OBJECTIVE: CYP2D6 plays a critical role in metabolizing tamoxifen into its active metabolite, endoxifen, which is crucial for its therapeutic effect in estrogen receptor-positive breast cancer. Single nucleotide polymorphisms (SNPs) in the CYP2D6 gen...
Middle Aged Polymorphism, Single Nucleotide Antineoplastic Agents, Hormonal Algorithms Tamoxifen Humans Female Cytochrome P-450 CYP2D6 Machine Learning Breast Neoplasms
View on PubMed DOI

Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.

Journal of the National Cancer Institute Dec 1, 2017
BACKGROUND: Aromatase inhibitors (AIs) are given as adjuvant therapy for hormone receptor-positive breast cancer in postmenopausal women, also to those with chemotherapy-induced ovarian function failure. The current analysis reports on endocrine data...
Clinical Trials, Phase III as Topic Middle Aged Ovarian Diseases Case-Control Studies Tamoxifen Estradiol Anastrozole Female Ovary Recovery of Function Adult Antineoplastic Agents, Hormonal Humans Randomized Controlled Trials as Topic Breast Neoplasms Chemotherapy, Adjuvant Prognosis Aromatase Inhibitors
View on PubMed DOI

Effects of treatment with chemotherapy and/or tamoxifen on the biomarkers of cardiac injury and oxidative stress in women with breast cancer.

Medicine Nov 1, 2017
There has been an increase in deaths from cardiovascular diseases following breast cancer therapy. Evidence has shown that this outcome is, in part, associated with cardiotoxicity induced by the chemotherapeutic drugs and the increase in oxidative st...
Glutathione Peroxidase Tamoxifen Advanced Oxidation Protein Products Time Factors Oxidative Stress Troponin I Female Middle Aged Breast Neoplasms Antineoplastic Agents Cardiovascular Diseases Humans Biomarkers
View on PubMed DOI

Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.

Acta reumatologica portuguesa Jan 1, 2015
Breast cancer is the most commonly diagnosed cancer among women, but despite survival rates improvement, it is still the second major cause of cancer related death. In postmenopausal women with estrogen receptor (ER) dependent breast cancer, hormone ...
Osteoporosis, Postmenopausal Fractures, Spontaneous Antineoplastic Agents, Hormonal Tamoxifen Breast Neoplasms Neoplasm Recurrence, Local Bone Density Conservation Agents Postmenopause Aromatase Inhibitors Receptors, Estrogen Humans Female
View on PubMed
Popular Topics
Recent Journals